Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma.

ABSTRACT:

Background

The response rate to sorafenib is limited for unresectable hepatocellular carcinoma (HCC). Little is known about the long-term outcomes of objective responders. The role of second-line therapies on the survival of sorafenib-responders is unclear. We aimed to delineate the long-term outcomes and the role of subsequent treatment after responding to sorafenib.

Methods

From September 2012 to December 2019, 922 patients who received sorafenib treatment for unresectable HCC were retrospectively reviewed. Of these, 21 (2.3%) achieved a complete response (CR) and 54 (5.9%) had a partial response (PR) based on mRECIST criteria. Factors associated with survivals were analyzed.

Results

During the median follow-up of 35.3 months, the median duration of response was 18.

SUBMITTER: Huang KW 

PROVIDER: S-EPMC9134461 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature